Orthox Ltd.: Funding, Investors & Team (Oct 2026)
Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.
Orthox Ltd. has raised $12.4M across 1 funding round on record, the most recent a Series A of $12.4M announced in Feb 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Orthox Ltd. Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Orthox Ltd. Funding Rounds
Orthox Ltd. Founders and Leadership Team
Contact details for the Orthox Ltd. team: 1 of 1 has an email address on file.
Start 14-day free trial →Orthox Ltd. Funding Compared to Other Biotechnology Startups
Orthox Ltd.'s latest round of $12.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orthox Ltd. in Biotechnology and Abingdon
Companies Similar to Orthox Ltd.
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Orthox Ltd. Funding FAQs
What does Orthox Ltd. do?
Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.
How much funding has Orthox Ltd. raised?
Orthox Ltd. has raised $12.4M across 1 round on record. The most recent is a Series A of $12.4M announced in Feb 2022.
When did Orthox Ltd. last raise funding?
Orthox Ltd.'s most recent funding round on record is a Series A of $12.4M, announced in Feb 2022.
Who is the CEO of Orthox Ltd.?
Nick Skaer is listed as CEO at Orthox Ltd..
Where is Orthox Ltd. headquartered?
Orthox Ltd. is based in Abingdon, Oxfordshire, United Kingdom.
How many employees does Orthox Ltd. have?
Orthox Ltd. is in the 11-50 employee band.
How does Orthox Ltd.'s funding compare to other Biotechnology startups?
Orthox Ltd.'s latest round of $12.4M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Orthox Ltd. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orthox Ltd. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.